Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma is a research paper published in Journal of Hepatocellular Carcinoma (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P50 CA217674
National Institutes of Health
Grant: 1R01CA247441-01A1
Vascularized tumor explants for drug testing
National Institutes of Health
Grant: 5P50CA217674-04
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
National Institutes of Health
Grant: 5R01CA260857-03
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
National Institutes of Health
Grant: 5R01CA260872-03
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
Fields of Study
Keywords
Sustainable Development Goals